EA201892605A1 - METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR - Google Patents

METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR

Info

Publication number
EA201892605A1
EA201892605A1 EA201892605A EA201892605A EA201892605A1 EA 201892605 A1 EA201892605 A1 EA 201892605A1 EA 201892605 A EA201892605 A EA 201892605A EA 201892605 A EA201892605 A EA 201892605A EA 201892605 A1 EA201892605 A1 EA 201892605A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
skin cancer
inhibitor
administration
treating skin
Prior art date
Application number
EA201892605A
Other languages
Russian (ru)
Inventor
Мэттью Г. Фьюри
Израэль Лови
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2017/032408 external-priority patent/WO2017197263A1/en
Publication of EA201892605A1 publication Critical patent/EA201892605A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способам лечения, снижения тяжести или ингибирования роста злокачественной опухоли (например, рака кожи). Способы по настоящему документу включают введение пациенту терапевтически эффективного количества антагониста белка программируемой клеточной гибели 1 (PD-1) (например, антитела против PD-1). В определенных вариантах осуществления рак кожи представляет собой плоскоклеточную карциному кожи или базальноклеточную карциному.The present invention relates to methods for treating, reducing, or inhibiting the growth of a malignant tumor (for example, skin cancer). The methods of this document include administering to a patient a therapeutically effective amount of a programmable cell death protein 1 (PD-1) antagonist (eg, antibodies against PD-1). In certain embodiments, skin cancer is squamous cell carcinoma of the skin or basal cell carcinoma.

EA201892605A 2017-01-27 2017-05-12 METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR EA201892605A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451274P 2017-01-27 2017-01-27
PCT/US2017/032408 WO2017197263A1 (en) 2016-05-13 2017-05-12 Methods of treating skin cancer by administering a pd-1 inhibitor

Publications (1)

Publication Number Publication Date
EA201892605A1 true EA201892605A1 (en) 2019-04-30

Family

ID=66436975

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892605A EA201892605A1 (en) 2017-01-27 2017-05-12 METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR
EA201892604A EA201892604A1 (en) 2017-01-27 2017-05-12 COMBINATION OF ANTIBODIES AGAINST PD-1 AND IRRADIATION FOR THE TREATMENT OF MALIGNANT TUMOR

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201892604A EA201892604A1 (en) 2017-01-27 2017-05-12 COMBINATION OF ANTIBODIES AGAINST PD-1 AND IRRADIATION FOR THE TREATMENT OF MALIGNANT TUMOR

Country Status (1)

Country Link
EA (2) EA201892605A1 (en)

Also Published As

Publication number Publication date
EA201892604A1 (en) 2019-04-30

Similar Documents

Publication Publication Date Title
MX2022001120A (en) Methods of treating skin cancer by administering a pd-1 inhibitor.
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
PH12018500642A1 (en) Anti-garp antibody
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
BR112016029916A2 (en) mnk inhibitors and related methods
MX2019007243A (en) Ectonucleotidase inhibitors and methods of use thereof.
IN2015KN00350A (en)
MX2022013390A (en) Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor.
MX2019009772A (en) Anti-pd-1 antibodies for treatment of lung cancer.
PH12021551126A1 (en) Humanized antibodies against c-kit
PE20200602A1 (en) MACROCICLIC COMPOUND AND ITS USES
MX2017006938A (en) Combination therapy for treatment of cancer.
BR112015026247A2 (en) methods for cancer treatment using tor kinase inhibitor combination therapy
EA201892541A1 (en) HUMANIZED ANTI-IL-1R3 ANTIBODIES
MX2019013862A (en) Combination therapy.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
BR112016023011A2 (en) gastric cancer treatment
PH12016000355B1 (en) Use of xanthophylls for the treatment of cancers
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.
EA201892605A1 (en) METHODS OF TREATING SKIN CANCER THROUGH ADMINISTRATION OF PD-1 INHIBITOR